Does percutaneous transluminal ablation of renal nerves (renal denervation) reduce blood pressure in patients with resistant hypertension?
This ESH position paper summarizes current evidence and provides practical recommendations for the use of renal denervation in treating resistant hypertension.
Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves renal denervation (RDN) as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.
Schmieder et al. (Sat,) studied this question.